SOAT1 and leukemia: Leukemia is a heterogenous disease, and patients often have unique mutations; however, clinical analysis has demonstrated that JAK/STAT pathway mutations are quite common [40], and the results from this study contribute to the growing body of knowledge that inhibiting JAK activity may be an effective strategy in treating hematological malignancies.